Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck to move COVID-19 treatment into large trials, sees sales recovering this year

07/31/2020 | 11:41am EDT
The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

Merck & Co on Friday said it plans to advance an antiviral treatment for COVID-19 into large studies in the coming weeks, and it forecast a more limited hit to full-year sales and profit from coronavirus lockdowns than it previously expected.

The U.S. drugmaker said two large trials of the oral antiviral being developed with Ridgeback Biotherapeutics would begin in September. Merck said it can manufacture "many millions of doses" of the drug before year end.

Gilead Sciences Inc's intravenous antiviral remdesivir is currently being widely used as a treatment for hospitalized COVID-19 patients.

Merck also expects its two experimental coronavirus vaccines to start human trials later this year, lagging some rivals who have begun late-stage studies.

The vaccine it picked up through its acquisition of Themis Bioscience should start clinical studies in the current quarter, while another being developed with nonprofit research organization IAVI should begin trials by year end.

Effective treatments and vaccines are seen as essential to halting a pandemic that has killed over 674,000 people worldwide and battered global economies.

Merck said it hopes its experimental coronavirus vaccines can be effective with a single dose

"In dealing with an aggressive, globally dispersed disease like COVID-19, we believe that it is wise to lower the barrier to vaccination as much as possible, for example, by launching a vaccine that is effective with just a single administration," Merck research head Roger Perlmutter said on a conference call.

Merck said it now expects a 2020 revenue decline of $1.95 billion due to the precipitous drop in medical visits early in the pandemic, from its prior estimate of $2.1 billion. The company said it expects a return to normal levels in the fourth quarter.

"Business conditions have clearly improved and ... we believe the healthcare system is better positioned to provide patient access as we move through the balance of the year," said Chief Financial Officer Robert Davis.

The company noted that it still had strong second-quarter sales from blockbuster cancer drug Keytruda. Keytruda sale rose nearly 29% to $3.39 billion, ahead of Wall Street expectations.

Total sales fell 7.6% to $10.87 billion due to a $1.6 billion pandemic-related hit in the quarter. That still exceeded analysts' estimates of $10.39 billion.

Merck raised its full-year adjusted profit forecast to $5.63 to $5.78 per share from a prior range of $5.17 and $5.37.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in Maplewood, New Jersey.; Editing by Bernard Orr, Jonathan Oatis and Bill Berkrot)

By Manas Mishra and Michael Erman

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -0.45% 67.05 Delayed Quote.15.09%
MERCK & CO., INC. -0.73% 76.19 Delayed Quote.-6.17%
All news about GILEAD SCIENCES, INC.
10:05aGILEAD SCIENCESá : to Present More Than 70 Abstracts From Diverse Liver Disease ..
10:05aGILEAD SCIENCESá : Veklury Associated With a Reduction in Mortality Rate in Hosp..
06:01aMastercard Foundation Appoints Robin Washington to Board of Directors
06/21GILEAD SCIENCESá : Says Veklury Lowers Mortality Rate in COVID-19 Treatment
06/21GILEAD SCIENCESá : remdesivir reduces COVID-19 mortality risk- data
06/21GILEAD SCIENCESá : Statement on New England Journal of Medicine Publication of P..
06/21GILEAD SCIENCESá : Veklury« (Remdesivir) Associated With a Reduction in Mortalit..
06/21GILEAD SCIENCESá : to Present More Than 70 Abstracts From Diverse Liver Disease ..
06/17GILEAD SCIENCESá : Kite Partners With Shoreline Biosciences to Develop Cancer Th..
06/17GILEAD SCIENCESá : Kite and Shoreline Biosciences Enter Into Strategic Partnersh..
More news
Financials (USD)
Sales 2021 24 680 M - -
Net income 2021 6 885 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 12,7x
Yield 2021 4,19%
Capitalization 84 093 M 84 093 M -
EV / Sales 2021 4,30x
EV / Sales 2022 4,25x
Nbr of Employees 13 600
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 67,05 $
Average target price 75,15 $
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.24.70%66 143
BIONTECH SE190.10%54 605
BEIGENE, LTD.28.69%30 138